Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

https://doi.org/10.1182/blood-2019-126385

Published: 2019

Journal Articles

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Blood (2019) 134 (Supplement_1): 1840.

https://doi.org/10.1182/blood-2019-125235

Published: 2019

Journal Articles

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Kaini Shen, MD, Yujun Dong, MD, Weijun Fu, Sr., MD PhD, Yu Wu, MD, Zhongxia Huang, Yongqiang Wei, PhD, Chunrui Li, MD PhD, Chunyan Sun, MD PhD, Wenrong Huang, Huihan Wang, MD PhD, Congli Zhang, Huilei Miao, Lu Zhang, MD, Xinxin Cao, MD, Daobin Zhou, MD, Jian Li, MD

Blood (2019) 134 (Supplement_1): 1870.

https://doi.org/10.1182/blood-2019-122087

Published: 2019

Journal Articles

The Effect of the Soluble Guanylate Cyclase Stimulator Olinciguat on Renal Function and Biomarkers of Inflammation and Renal Injury in Sickle Cell Mice

Boris Tchernychev, PhD, Raghunath Ramanarasimhaiah, MD, Guang Liu, PhD, Katherine Hall, PhD, Regina Margaret Graul, PhD, Jaime Masferrer, PhD

Blood (2019) 134 (Supplement_1): 3554.

https://doi.org/10.1182/blood-2019-127361

Published: 2019

Journal Articles

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Sally Arai, MD, Richard Lafayette, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1828.

https://doi.org/10.1182/blood-2019-122152

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Faye Amelia Sharpley, BA MA MSc MBBChir FRCPath, Hannah Victoria Giles, FRCPath, MRCP, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Carol J Whelan, Philip N Hawkins, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 4375.

https://doi.org/10.1182/blood-2019-128175

Published: 2019

Journal Articles

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Agrima Mian, MBBS, MD, Albert Aboseif, DO, Wei Wei, MS, Rajshekhar Chakraborty, MD, Jack Khouri, MD, Joslyn Rudoni, PharmD, Allison M. Winter, MD, Sonam Patel, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Brad Pohlman, MD, Stephanie Berg, DO, James R. Cook, MD PhD, Brian T. Hill, MD, Alex V. Mejia Garcia, MD

Blood (2019) 134 (Supplement_1): 5248.

https://doi.org/10.1182/blood-2019-130396

Published: 2019

Journal Articles

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Rodney H Falk, MD, Morie A Gertz, MD, Merrill D Benson, MD, Gustavo Buchele, MD PhD, Michela Brambatti, MD MS, Sotirios Tsimikas, MD, Nicholas J Viney, Bsc, Li-Jung Tai, MD PhD, Cecilia Monteiro, MD PhD, Qingqing Yang, MS, Louis St L O'Dea, MB B.Ch. BAO, FRCP, Ewa Karwatowska-Prokopczuk, MD PhD, Eugene Schneider, MD, Richard S Geary, PhD, Brett P Monia, PhD

Blood (2019) 134 (Supplement_1): 5764.

https://doi.org/10.1182/blood-2019-129269

Published: 2019

Journal Articles

Histopathology of Chronic Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: A Multi-Center Observational Study of Kidney Biopsies

Feng Chen, MD PhD, Depei Wu, MD PhD, Ran Wang, MD, Xianghua Huang, MD PhD, Xiaozhong Li, MD PhD, Chaoxing Huang, MD PhD

Blood (2019) 134 (Supplement_1): 5696.

https://doi.org/10.1182/blood-2019-128121

Published: 2019

Journal Articles

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Vishal K Gupta, MD, Dina Brauneis, NP, Anthony C Shelton, RN, Karen Quillen, MD MPH, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2018) 132 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2018-99-111551

Published: 2018

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Blood (2018) 132 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2018-99-112851

Published: 2018

Journal Articles

Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Sarah S Lee, MD, Nathaniel Rosko, PharmD, Bhumika J. Patel, MD, Madeline Waldron, PharmD, Jackie Tomer, MPH, Roman Goldman, CNP, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Saveta Mathur, CNP, Christy J. Samaras, DO, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2018-99-119979

Published: 2018

Journal Articles

Allergic Sensitization Is Associated with Decreased Risk of ED Visits and Hospitalizations for Pain in Sickle Cell Disease

Christy Sadreameli, MD, M.H.S., Benjamin Kopp, MD, M.P.H., Susan E Creary, MD, Emily Jacobs, B.S., John J Strouse, MD PhD, Sharon A. McGrath-Morrow, MD, James F. Casella, MD, Elizabeth C. Matsui

Blood (2018) 132 (Supplement 1): 3676.

https://doi.org/10.1182/blood-2018-99-119743

Published: 2018

Journal Articles

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

Anita D'Souza, MBBS, Kathryn E Flynn, PhD, Binod Dhakal, MBBS, Saurabh Chhabra, MD, Marcelo C Pasquini, MDMS, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2018-99-114783

Published: 2018

Journal Articles

Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Ali Alahmari, MD, Jeffrey H. Lipton, MD PhD, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 2880.

https://doi.org/10.1182/blood.V130.Suppl_1.2880.2880

Published: 2017

Journal Articles

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Salli Fennessey, Anthony C Shelton, RN

Blood (2017) 130 (Supplement 1): 507.

https://doi.org/10.1182/blood.V130.Suppl_1.507.507

Published: 2017

Journal Articles

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

Kiyoshi Okazuka, MD, Nobuhiro Tsukada, Kota Sato, MD, Kanji Miyazaki, Yumiko Yoshiki, Yu Abe, MD, Tadao Ishida, MD, Kenshi Suzuki

Blood (2017) 130 (Supplement 1): 4542.

https://doi.org/10.1182/blood.V130.Suppl_1.4542.4542

Published: 2017

Journal Articles

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Imad Ud Deen, MBBS, Muhammad Umar Khalid, MD, Atlantis Dawn Russ, MD PhD, Anh Hua, BS, Ahmad Iftikhar, MD, Adeela Mushtaq, MD, Ahmad Safdar, BS, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5399.

https://doi.org/10.1182/blood.V130.Suppl_1.5399.5399

Published: 2017

NARROW

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

The Effect of the Soluble Guanylate Cyclase Stimulator Olinciguat on Renal Function and Biomarkers of Inflammation and Renal Injury in Sickle Cell Mice

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Histopathology of Chronic Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: A Multi-Center Observational Study of Kidney Biopsies

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Allergic Sensitization Is Associated with Decreased Risk of ED Visits and Hospitalizations for Pain in Sickle Cell Disease

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only